Lurasidone-d8

CAT: 0804-HY-B0032ASSize: 1 mgDry Ice: NoHazardous: No
CAT#:0804-HY-B0032ASSize:1 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Lurasidone-d8 is deuterium labeled Lurasidone. Lurasidone (SM-13496) is an antagonist of both dopamine D2 and 5-HT7 with IC50s of 1.68 and 0.495 nM, respectively. Lurasidone (SM-13496) is also a partial agonist of 5-HT1A receptor with an IC50 of 6.75 nM.
CAS Number
[1132654-54-6]
Product Name Alternative
SM-13496-d8
UNSPSC
12352005
Hazard Statement
H302+H312+H332-H315-H317-H319-H361
Target
5-HT Receptor; Dopamine Receptor
Type
Isotope-Labeled Compounds
Related Pathways
GPCR/G Protein; Neuronal Signaling
Applications
Neuroscience-Neuromodulation
Field of Research
Neurological Disease
Solubility
10 mM in DMSO
Smiles
O=C1[C@@]2([H])[C@](C(N1C[C@H]3[C@@H](CCCC3)CN4C([2H])([2H])C([2H])([2H])N(C5=NSC6=CC=CC=C56)C([2H])([2H])C4([2H])[2H])=O)([H])[C@H]7C[C@@H]2CC7
Molecular Formula
C28H28D8N4O2S
Molecular Weight
500.73
Precautions
P261-P264-P270-P271-P272-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P405-P501
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Ishibashi T, et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther. 2010 Jul;334 (1) :171-81.|[3]Sakine Atila Karaca, et al. Development of a validated high-performance liquid chromatographic method for the determination of Lurasidone in pharmaceuticals. Marmara Pharm J. 2017;21 (4) : 931-937.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported
Isoform
5-HT1 Receptor;5-HT7 Receptor

Popular Products